Microneedle technology is being developed for peptide and proteins as a patient-friendly alternative to subcutaneous and intravenous injection. While several microneedle formats are in early development Zosano has focused on drug-coated microneedle patch optimization. This talk will highlight our technology validation in clinical trials. Our studies demonstrate that delivery of parathyroid hormone peptide (PTH 1-34) is feasible for the treatment of severe osteoporosis and warrants further clinical development toward approval of the first commercial microneedle patch product.

Biography

Peter Daddona is founder and Chief Scientific Officer of Zosano Pharma, a spin out company from ALZA Corp/J&J. He is responsible for strategic planning and research/early development. Prior to that he was VP of Macroflux® Technology Development at ALZA/J&J and Consulting Associate Professor of Dermatology at Stanford University. Before joining ALZA, he served as Vice President, Immunobiology Research at Centocor/J&J.